Dosing in Mild Renal Impairment
| Dose Information |
|---|
Graph Information
INVEGA SUSTENNA® Dosing in Mild Renal Impairment
Consistent with the INVEGA SUSTENNA® Prescribing Information:
- For patients with mild renal impairment [creatinine clearance ≥ 50 mL/min to < 80 mL/min (Cockcroft-Gault Formula)], initiate with 156 mg followed by 117 mg one week later. Administer both doses in the deltoid muscle.
Thereafter, follow with monthly maintenance injections of 78 mg in either the deltoid or gluteal muscle which can be adjusted within the range of 39 mg to 156 mg based on tolerability and/or efficacy. The maximum monthly dose is 156 mg for patients with mild renal impairment. The 39 mg strength was not studied in the long-term schizoaffective disorder study.
- INVEGA SUSTENNA® is not recommended in patients with moderate or severe renal impairment (creatinine clearance < 50 mL/min).
- Administration: Each injection must be administered only by a healthcare professional. INVEGA SUSTENNA® is intended for intramuscular use only. Do not administer by any other route. Avoid inadvertent injection into a blood vessel.
INVEGA SUSTENNA® Prescribing Information [http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf]